多年来临床上把有子宫内膜癌史的妇女列为雌激素替代疗法的禁忌症,但近14年来已有相当多的报道提示可以使用该疗法。1985年用非随机研究评估221例Ⅰ期子宫内膜癌,其中47例(22%)治愈后出现血管舒缩症状。雌激素替代疗法组仅1例(2. 1%)复发,未用组174例中26例(14. 9%)复发,两组相比,P=0. 0147。替代疗法组死亡1例与未用组死亡26例相比,P=0. 014,未用组死于癌症16例,死于并发症10例。用多因素分析法分析了伴有多种复发因素的子宫内膜癌妇女,比较了使用替代疗法与未使用 For many years, women with a history of endometrial cancer have been clinically contraindicated in estrogen replacement therapy, but there has been considerable reporting over the past 14 years that the therapy is available. In a non-randomized study in 1985, 221 patients with stage I endometrial cancer were evaluated, of whom 47 (22%) developed vasomotor symptoms. In the estrogen replacement therapy group, only 1 patient (2.1%) relapsed, and 26 patients (14.9%) had relapse in the unused group, P = 0.0147. One patient died in the replacement therapy group compared with 26 patients in the unused group, P = 0.014. In the unused group, 16 patients died of cancer and 10 patients died of complications. Multivariate analysis was used to analyze women with endometrial cancer with multiple recurrence factors and to compare the use of alternative therapy with unused